ID: ALA3311526

Max Phase: Preclinical

Molecular Formula: C17H20O8

Molecular Weight: 352.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  CO[C@H]1O[C@H](CO)[C@H](O)[C@H](OCc2cc3ccccc3oc2=O)[C@H]1O

Standard InChI:  InChI=1S/C17H20O8/c1-22-17-14(20)15(13(19)12(7-18)25-17)23-8-10-6-9-4-2-3-5-11(9)24-16(10)21/h2-6,12-15,17-20H,7-8H2,1H3/t12-,13+,14-,15+,17+/m1/s1

Standard InChI Key:  SEGZMJNGWKYDDQ-NMNMXBMNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 352.34

Molecular Weight (Monoisotopic): 352.1158

AlogP: -0.24

#Rotatable Bonds: 5

Polar Surface Area: 118.59

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.28

CX Basic pKa:

CX LogP: -0.23

CX LogD: -0.23

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.63

Np Likeness Score: 1.40

References

1. Rajput VK, Leffler H, Nilsson UJ, Mukhopadhyay B..  (2014)  Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.,  24  (15): [PMID:24973029] [10.1016/j.bmcl.2014.05.063]

Source

Source(1):

• Scientific Literature